Advanced search
Publication Cover
Journal of Immunotoxicology Volume 6, 2009 - Issue 4: Select Reports from the “Cancer Immunotherapy and Immunomonitoring (CITIM)” Conference, May 18-21, 2009, Kiev, Ukraine
Submit an article Journal homepage
2,913
Views
46
CrossRef citations to date
0
Altmetric
KIEV MEETING: Oral Presentations

ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring—even in hands of ELISPOT-inexperienced investigators

W. ZhangCellular Technology Ltd., Shaker Hts. Ohio, USA
,
R. CaspellCellular Technology Ltd., Shaker Hts. Ohio, USA
,
A. Y. KarulinCellular Technology Ltd., Shaker Hts. Ohio, USA
,
M. AhmadNottingham Trent University, Nottingham, UK
,
N. HaicheurHôpital Européen Georges Pompidou, Paris, France
,
A. AbdelsalamUniversity of Pittsburgh, Pittsburgh, PA, USA
,
K. JohannesenNorwegian Radium Institute, Oslo, Norway
,
V. VignardINSERM, Nantes, France
,
P. DudzikJagiellonian University Medical College, Krakow, Poland
,
K. GeorgakopoulouImmunology Center, St. Savas Cancer Hospital, Athens, Greece
,
A. MihaylovaUMBAL “Alexandrovska”, Sofia, Bulgaria
,
K. SilinaBiomedical Research Study Centre, Riga, Latvia
,
N AptsiauriHospital Universitario Virgen De la Nieves, Granada, Spain
,
V. AdamsOnyvax Ltd, London, UK
,
P. V. LehmannCorrespondence[email protected]
&
S. McArdleNottingham Trent University, Nottingham, UK
 show all
Pages 227-234 | Received 27 Jul 2009, Accepted 08 Sep 2009, Published online: 12 Nov 2009

References

  • Britten, C. M., Janetzki, S., van der Burg, S. H., Gouttefangeas, C., and Hoos, A. 2007 Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol. Immunother. 57:285–288.
  • Britten, C. M., Janetzki, S., Ben-Porat, L., Clay, T. M., Kalos, M., Maecker, H., Odunsi, K., Pride, M., Old, L., Hoos, A., and Romero, P. 2009. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large-scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol. Immunother. DOI 10.1007/s00262-009-0681-z.
  • Cox, J. H., Ferrari, G., Kalams, S. A., Lopaczynski, W., Oden, N., and D’souza, M. P. 2005. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retrovirus. 21:68–81.
  • Currier, J. R., Kuta, E. G., Turk, E., Earhart, L. B., Loomis-Price, L., Janetzki, S., Ferrari, G., Birx, D. L., and Cox, J. H. 2002. A panel of MHC Class I- restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Meth. 260:157–172.
  • Hesse, M. D., Karulin, A. Y., Boehm, B. O., Lehmann, P. V., and Tary-Lehmann, M. 2001. A T-cell clone’s avidity is a function of its activation state. J. Immunol. 167:1353–1361.
  • Janetzki, S., Panageas, K. S., Ben-Porat, L., Boyer, J., Britten, C. M., Clay, T. M., Kalos, M., Maecker, H. T., Romero, P., Yuan, J., Kast, W. M., and Hoos, A. 2008. Results and harmonization guidelines from two large-scale international ELISPOT proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 57:303–315.
  • Kreher, C. R., Dittrich, M. T., Guerkov, R., Boehm, B. O., and Tary-Lehmann, M. 2003. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J. Immunol. Meth. 278:79–93.
  • Lehmann, P. V., Cardinaux, F., Appella, E., Muller, S., Falcioni, F., Adorini, L., and Nagy, Z. A. 1989. Inhibition of T-cell response with peptides is influenced by both peptide-binding specificity of major histocompatibility complex molecules and susceptibility of T-cells to blocking. Eur. J. Immunol. 19:1071–1077.
  • Maecker, H. T., Hassler, J., Payne, J. K., Summers, A., Comatas, K., Ghanayem, M., Morse, M. A., Clay, T. M., Lyerly, H. K., Bhatia, S., Ghanekar, S. A., Maino, V. C., Delarosa, C., and Disis, M. L. 2008. Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 9:9.
  • Targoni, O. S., and Lehmann, P. V. 1998. Endogenous myelin basic protein inactivates the high avidity T-cell repertoire. J. Exp. Med. 187:2055–2063.
  • van der Burg, S. H. 2008. Therapeutic vaccines in cancer: Moving from immunomonitoring to immunoguiding. Expert Rev. Vaccines 7:1–5.
  • Wills, M., Carmichael, A., Mynard, K., Jin, X., Weekes, M., Plachter, B., and Sissons, J. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569–7579.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.